Biogen Inc (BIIB) has fallen Wednesday morning, with the stock falling -2.82% in pre-market trading to 287.2. BIIB's short-term technical score of 43 indicates that the stock has traded less bullishly over the last month than 57% of stocks on the market. In the Drug Manufacturers - General industry, which ranks 128 out of 146 industries, BIIB ranks higher than 57% of stocks. Biogen Inc has fallen 13.52% over the past month, closing at $342.75 on August 25. During this period of time, the stock fell as low as $295.95 and as high as $347.74. BIIB has an average analyst recommendation of Buy. The company has an average price target of $406.89.
BIIB has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on BIIB!